Drug Profile
Research programme: antibody drug conjugates - Avicenna Oncology
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Avicenna Oncology
- Class Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in Switzerland
- 04 Aug 2016 Research programme: antibody drug conjugates - Avicenna Oncology is available for licensing as of 21 Jul 2016. http://www.avicenna-oncology.com/
- 15 Jul 2016 Early research in Cancer in Switzerland (unspecified route) (Avicenna Oncology pipeline, July 2016)